Clinical markers for identifying cholinergic deficits in Parkinson's disease

Movement Disorders

Volumn 30, Issue 2, 2015, Pages 269-273

  Müller, Martijn L T M ^a   Bohnen, Nicolaas I ^a,b   Kotagal, Vikas ^a   Scott, Peter J H ^a   Koeppe, Robert A ^a   Frey, Kirk A ^a   Albin, Roger L ^a,b  

^a UNIVERSITY OF MICHIGAN   (United States)

^b VAAAHS   (United States)

Author keywords

Acetylcholine; Acetylcholinesterase; Biomarkers; Parkinson's disease; PET

Indexed keywords

ACETYLCHOLINESTERASE; CHOLINERGIC RECEPTOR STIMULATING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; PMP C 11; TRACER; UNCLASSIFIED DRUG; ACETYLCHOLINE; BIOLOGICAL MARKER; DOPAMINE;

AGED; AREA UNDER THE CURVE; ARTICLE; CHOLINERGIC ACTIVITY; CHOLINERGIC DENERVATION; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DENERVATION; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE MARKER; FEMALE; FOREBRAIN; HUMAN; MAJOR CLINICAL STUDY; MALE; MONTREAL COGNITIVE ASSESSMENT; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PARASOMNIA; PARASYMPATHETIC INNERVATION; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; REM SLEEP; RETROSPECTIVE STUDY; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SUBSTITUTION THERAPY; WALKING SPEED; ADULT; CHOLINERGIC NERVE CELL; METABOLISM; MIDDLE AGED; PROCEDURES; REM SLEEP BEHAVIOR DISORDER; VERY ELDERLY;

ACETYLCHOLINE; ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS; CHOLINERGIC NEURONS; DOPAMINE; FEMALE; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE; POSITRON-EMISSION TOMOGRAPHY; REM SLEEP BEHAVIOR DISORDER; RETROSPECTIVE STUDIES;

EID: 84961291182     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.26061     Document Type: Article

References (32)

1. Langston JW. The Parkinson's complex: parkinsonism is just the tip of the iceberg. Ann Neurol 2006;59:591-596.
2. Muller ML, Bohnen NI. Cholinergic dysfunction in Parkinson's disease. Curr Neurol Neurosci Rep 2013;13:377.
3. Svenningsson P, Westman E, Ballard C, Aarsland D. Cognitive impairment in patients with Parkinson's disease: diagnosis, biomarkers, and treatment. Lancet Neurol 2012;11:697-707.
4. Dubois B, Danze F, Pillon B, Cusimano G, Lhermitte F, Agid Y. Cholinergic-dependent cognitive deficits in Parkinson's disease. Ann Neurol 1987;22:26-30.
5. Bohnen NI, Kaufer DI, Hendrickson R, et al. Cognitive correlates of cortical cholinergic denervation in Parkinson's disease and parkinsonian dementia. J Neurol 2006;253:242-247.
6. Bohnen NI, Muller ML, Kotagal V, et al. Olfactory dysfunction, central cholinergic integrity and cognitive impairment in Parkinson's disease. Brain 2010;133:1747-1754.
7. Bohnen NI, Muller ML, Kotagal V, et al. Heterogeneity of cholinergic denervation in Parkinson's disease without dementia. J Cereb Blood Flow Metab 2012;32:1609-1617.
8. Yarnall A, Rochester L, Burn DJ. The interplay of cholinergic function, attention, and falls in Parkinson's disease. Mov Disord 2011;26:2496-2503.
9. Chung KA, Lobb BM, Nutt JG, Horak FB. Effects of a central cholinesterase inhibitor on reducing falls in Parkinson disease. Neurology 2010;75:1263-1269.
10. Bohnen NI, Muller ML, Koeppe RA, et al. History of falls in Parkinson disease is associated with reduced cholinergic activity. Neurology 2009;73:1670-1676.
11. Bohnen NI, Frey KA, Studenski S, et al. Gait speed in Parkinson disease correlates with cholinergic degeneration. Neurology 2013;81:1611-1616.
12. Kotagal V, Albin RL, Muller ML, et al. Symptoms of rapid eye movement sleep behavior disorder are associated with cholinergic denervation in Parkinson disease. Ann Neurol 2012;71:560-568.
13. Bohnen NI, Muller ML. In vivo neurochemical imaging of olfactory dysfunction in Parkinson's disease. J Neural Transm 2013;120:571-576.
14. Kotagal V, Albin RL, Muller ML, Koeppe RA, Frey KA, Bohnen NI. Gender differences in cholinergic and dopaminergic deficits in Parkinson disease. J Neural Transm 2013;120:1421-1424.
15. Goetz CG, Poewe W, Rascol O, et al. Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and recommendations. Mov Disord 2004;19:1020-1028.
16. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967;17:427-442.
17. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-184.
18. Bohnen NI, Albin RL, Koeppe RA, et al. Positron emission tomography of monoaminergic vesicular binding in aging and Parkinson disease. J Cereb Blood Flow Metab 2006;26:1198-1212.
19. Doty RL, Shaman P, Dann M. Development of the University of Pennsylvania Smell Identification Test: a standardized microencapsulated test of olfactory function. Physiol Behav 1984;32:489-502.
20. Doty RL, Shaman P, Kimmelman CP, Dann MS. University of Pennsylvania Smell Identification Test: a rapid quantitative olfactory function test for the clinic. Laryngoscope 1984;94:176-178.
21. Nasreddine ZS, Phillips NA, Bedirian V, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 2005;53:695-699.
22. Boeve BF, Molano JR, Ferman TJ, et al. Validation of the Mayo Sleep Questionnaire to screen for REM sleep behavior disorder in an aging and dementia cohort. Sleep Med 2011;12:445-453.
23. Muller ML, Albin RL, Kotagal V, et al. Thalamic cholinergic innervation and postural sensory integration function in Parkinson's disease. Brain 2013;136:3282-3289.
24. 11C]-labeled radiopharmaceuticals using a Tracerlab FXC-Pro. J Label Compd Radiopharm 2011;54:819-838.
25. 11C]MP4A using a high-radioactivity brain region that represents an integrated input function for measurement of cerebral acetylcholinesterase activity without arterial blood sampling. J Cereb Blood Flow Metab 2001;21:1354-1366.
26. Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003;24:197-211.
27. Sohn YH, Kim JS. The influence of white matter hyperintensities on the clinical features of Parkinson's disease. Yonsei Med J 1998;39:50-55.
28. Kotagal V, Albin RL, Muller ML, Koeppe RA, Frey KA, Bohnen NI. Diabetes is associated with postural instability and gait difficulty in Parkinson disease. Parkinsonism Relat Disord 2013;19:522-526.
29. Kotagal V, Albin RL, Muller ML, Koeppe RA, Frey KA, Bohnen NI. Modifiable cardiovascular risk factors and axial motor impairments in Parkinson disease. Neurology 2014;82:1514-1520.
30. Lee SJ, Kim JS, Yoo JY, et al. Influence of white matter hyperintensities on the cognition of patients with Parkinson disease. Alzheimer Dis Assoc Disord 2010;24:227-233.
31. Muller ML, Frey KA, Petrou M, et al. β-amyloid and postural instability and gait difficulty in Parkinson's disease at risk for dementia. Mov Disord 2013;28:296-301.
32. Grimbergen YA, Langston JW, Roos RA, Bloem BR. Postural instability in Parkinson's disease: the adrenergic hypothesis and the locus coeruleus. Expert Rev Neurother 2009;9:279-290.